|
FDA Needs Independent Ethics Board To Assess Postmarket Studies
An independent ethics advisory board could help the FDA assess the risks and benefits of approved drugs and firm up its decisionmaking on required postmarket trials, according to a new report that advocates creating such a group.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives